+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

  • PDF Icon


  • 32 Pages
  • April 2020
  • Region: Global
  • GlobalData
  • ID: 5024538
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report


This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.


This report is required reading for -
  • Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months
  • Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.
  • Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.

Reasons to Buy
  • Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease
  • Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area
  • Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic
  • Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment

Table of Contents

1 Executive Summary

2 Table of Contents

3 Venture Capital Trends

4 Investors in Biopharmas

5 Regional Breakout

6 Companies with Venture Capital at Risk

7 Key Findings

8 Appendix

List of Tables
Table 1: Q1 2020: Top Companies by Venture Capital Amount
Table 2: Top Therapeutic Areas Receiving Venture Capital (2020)
Table 3: Most Active Investors by Deal Volume: Q1 2020
Table 4: Most Active Investors by Deal Value: Q1 2020
Table 5: 2019: Top Investors by Deal Count
Table 6: 2019 VC Invested by Region (by Recipient HQ Location)
Table 7: Companies Actively Looking to Close Venture Capital Rounds
Table 8: Biopharma Companies with Planned Series A Financing
Table 9: Sample of Biopharma Companies with Expected Series B Financing
Table 10: Sample of Biopharma Companies with Expected Series C Financing
Table 11: Sample of Biopharma Companies with Expected Series D Financing

List of Figures
Figure 1: Venture Capital Deals by Month
Figure 2: Venture Capital Deal Value 2019 FY vs. 2020 ($M)
Figure 3: Deal Volume by Series
Figure 4: Deal Value by Series
Figure 5: VC for Infectious Diseases Drugs Table
Figure 6: Top Investors by Deal Count - Q1 2020 vs. 2019
Figure 7: Spread of COVID-19
Figure 8: Venture Capital Deals in China
Figure 9: Venture Capital Deals in the US

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 4d Molecular Therapeutics
  • Adlai Nortye Biopharma Co Ltd.
  • AIVITA Biomedical, Inc.
  • Akouos Inc
  • Alexandria Venture Investments
  • Aligos Therapeutics Inc
  • ALX Oncology Inc
  • Amal Therapeutics SA
  • Annexon, Inc
  • Ansun BioPharma Inc
  • Antiva Biosciences
  • Apexigen, Inc.
  • Aqualung Therapeutics Corp
  • ARCH Venture Partners LP
  • ARS Pharmaceuticals, Inc.
  • Ascentage Pharma group
  • Atomwise Inc.
  • Biopact Cellular Transport Inc
  • Blueberry Therapeutics Ltd.
  • Boxer Capital
  • BW Therapeutics LLC
  • Cadent Therapeutics
  • Carisma Therapeutics Inc.
  • Casdin Capital LLC
  • Casma Therapeutics, Inc.
  • Celsense Inc
  • CerFlux Inc
  • Chondrial Therapeutics LLC
  • Cormorant Asset Management LLC
  • Cowen Healthcare Investments
  • Decibel Therapeutics, Inc.
  • Deerfield Management
  • ElevateBio LLC
  • Emulate Inc.
  • EQRx Inc
  • Escient Pharmaceuticals, Inc.
  • Evox Therapeutics Ltd
  • Fidelity Management & Research
  • Foresite Capital Management LLC
  • Freeline Therapeutics
  • Galecto Biotech AB
  • Galera Therapeutics Inc
  • Generation Bio Corp
  • Heartseed Inc
  • Horama SA
  • Hotspot Therapeutics, Inc
  • Hoverink Biotechnologies Inc
  • ILiAD Biotechnologies, LLC
  • Immune-Onc Therapeutics, Inc.
  • Immunocore Ltd
  • Impact Therapeutics
  • InCarda Therapeutics, Inc.
  • InSightec Ltd
  • Intarcia Therapeutics Inc
  • Intensity Therapeutics, Inc.
  • iTeos Therapeutics SA
  • KAHR medical Ltd
  • Kaitai Capital
  • Kallyope Inc
  • Kleo Pharmaceuticals Inc
  • Ksq Therapeutics, Inc
  • Kymera Therapeutics LLC
  • Lilly Asia Ventures
  • Max Biopharma Inc
  • Medicxi Ventures (UK) LLP
  • Metacrine, Inc.
  • Minoryx Therapeutics
  • Modalis Therapeutics Corporation
  • Nanjing Legend Biotech Co Ltd
  • NBE-Therapeutics AG
  • Neuraly, Inc
  • Neurana Pharmaceuticals, Inc.
  • Neurotez Inc
  • NMD Pharma ApS
  • Nohla Therapeutics, Inc.
  • Novo Holdings AS
  • Oncoheroes Biosciences Inc
  • OncoResponse, Inc.
  • Orasis Pharmaceuticals
  • Orbimed Advisors LLC
  • Partner Therapeutics, Inc
  • Perceptive Advisors
  • Phylos Bioscience Inc
  • Pliant Therapeutics Inc
  • Polaris Partners LLC
  • Quentis Therapeutics, Inc.
  • RA Capital Management LLC
  • Rakuten Medical Inc
  • Rallybio, LLC
  • ReAlta Life Sciences Inc
  • Redmile Group LLC
  • Relay Therapeutics
  • RemeGen Ltd
  • Rgenix, Inc
  • Rheos Medicines, Inc.
  • Ripple therapeutics Corp
  • Rongchang Bio-Pharmaceutical Co., Ltd
  • Sen-Jam Pharmaceutical LLC
  • Senti Biosciences, Inc
  • Sirnaomics, Inc.
  • Slayback Pharma LLC
  • SQZ Biotech
  • StemBioSys Inc
  • Surveyor Capital Ltd
  • SutroVax Inc
  • Synthego Corporation
  • Tecnologia Regenerativa Qrem SL
  • Transcenta Holding Ltd
  • Vedanta Biosciences, Inc.
  • Velicept Therapeutics, Inc.
  • Vivo Capital LLC
  • Xilio Therapeutics Inc
  • XtalPi, Inc.